282 related articles for article (PubMed ID: 34854890)
1. Isocitrate dehydrogenase gene variants in cancer and their clinical significance.
Cadoux-Hudson T; Schofield CJ; McCullagh JSO
Biochem Soc Trans; 2021 Dec; 49(6):2561-2572. PubMed ID: 34854890
[TBL] [Abstract][Full Text] [Related]
2. Isocitrate dehydrogenase variants in cancer - Cellular consequences and therapeutic opportunities.
Liu S; Cadoux-Hudson T; Schofield CJ
Curr Opin Chem Biol; 2020 Aug; 57():122-134. PubMed ID: 32777735
[TBL] [Abstract][Full Text] [Related]
3. Characterisation of isocitrate dehydrogenase 1/isocitrate dehydrogenase 2 gene mutation and the d-2-hydroxyglutarate oncometabolite level in dedifferentiated chondrosarcoma.
Mohammad N; Wong D; Lum A; Lin J; Ho J; Lee CH; Yip S
Histopathology; 2020 Apr; 76(5):722-730. PubMed ID: 31609487
[TBL] [Abstract][Full Text] [Related]
4. Isocitrate dehydrogenase 1 and 2 mutations, 2-hydroxyglutarate levels, and response to standard chemotherapy for patients with newly diagnosed acute myeloid leukemia.
Brunner AM; Neuberg DS; Wander SA; Sadrzadeh H; Ballen KK; Amrein PC; Attar E; Hobbs GS; Chen YB; Perry A; Connolly C; Joseph C; Burke M; Ramos A; Galinsky I; Yen K; Yang H; Straley K; Agresta S; Adamia S; Borger DR; Iafrate A; Graubert TA; Stone RM; Fathi AT
Cancer; 2019 Feb; 125(4):541-549. PubMed ID: 30422308
[TBL] [Abstract][Full Text] [Related]
5. Isocitrate dehydrogenase mutation as a therapeutic target in gliomas.
Han CH; Batchelor TT
Chin Clin Oncol; 2017 Jun; 6(3):33. PubMed ID: 28705010
[TBL] [Abstract][Full Text] [Related]
6. Natural and synthetic 2-oxoglutarate derivatives are substrates for oncogenic variants of human isocitrate dehydrogenase 1 and 2.
Liu X; Reinbold R; Liu S; Herold RA; Rabe P; Duclos S; Yadav RB; Abboud MI; Thieffine S; Armstrong FA; Brewitz L; Schofield CJ
J Biol Chem; 2023 Feb; 299(2):102873. PubMed ID: 36621625
[TBL] [Abstract][Full Text] [Related]
7. Metabolic adaptations in cancers expressing isocitrate dehydrogenase mutations.
Hvinden IC; Cadoux-Hudson T; Schofield CJ; McCullagh JSO
Cell Rep Med; 2021 Dec; 2(12):100469. PubMed ID: 35028610
[TBL] [Abstract][Full Text] [Related]
8. 2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutations.
Jin G; Reitman ZJ; Spasojevic I; Batinic-Haberle I; Yang J; Schmidt-Kittler O; Bigner DD; Yan H
PLoS One; 2011 Feb; 6(2):e16812. PubMed ID: 21326614
[TBL] [Abstract][Full Text] [Related]
9. The potential for isocitrate dehydrogenase mutations to produce 2-hydroxyglutarate depends on allele specificity and subcellular compartmentalization.
Ward PS; Lu C; Cross JR; Abdel-Wahab O; Levine RL; Schwartz GK; Thompson CB
J Biol Chem; 2013 Feb; 288(6):3804-15. PubMed ID: 23264629
[TBL] [Abstract][Full Text] [Related]
10. Isocitrate dehydrogenase mutations: new opportunities for translational research.
Keum YS; Choi BY
BMB Rep; 2015 May; 48(5):266-70. PubMed ID: 25787993
[TBL] [Abstract][Full Text] [Related]
11. Development of Novel Therapeutics Targeting Isocitrate Dehydrogenase Mutations in Cancer.
Sharma H
Curr Top Med Chem; 2018; 18(6):505-524. PubMed ID: 29773061
[TBL] [Abstract][Full Text] [Related]
12. Noninvasive assessment of isocitrate dehydrogenase mutation status in cerebral gliomas by magnetic resonance spectroscopy in a clinical setting.
Tietze A; Choi C; Mickey B; Maher EA; Parm Ulhøi B; Sangill R; Lassen-Ramshad Y; Lukacova S; Østergaard L; von Oettingen G
J Neurosurg; 2018 Feb; 128(2):391-398. PubMed ID: 28298040
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic value of plasma and urinary 2-hydroxyglutarate to identify patients with isocitrate dehydrogenase-mutated glioma.
Lombardi G; Corona G; Bellu L; Della Puppa A; Pambuku A; Fiduccia P; Bertorelle R; Gardiman MP; D'Avella D; Toffoli G; Zagonel V
Oncologist; 2015 May; 20(5):562-7. PubMed ID: 25862748
[TBL] [Abstract][Full Text] [Related]
14. Identification of additional IDH mutations associated with oncometabolite R(-)-2-hydroxyglutarate production.
Ward PS; Cross JR; Lu C; Weigert O; Abel-Wahab O; Levine RL; Weinstock DM; Sharp KA; Thompson CB
Oncogene; 2012 May; 31(19):2491-8. PubMed ID: 21996744
[TBL] [Abstract][Full Text] [Related]
15. Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase Inhibition.
Harding JJ; Lowery MA; Shih AH; Schvartzman JM; Hou S; Famulare C; Patel M; Roshal M; Do RK; Zehir A; You D; Selcuklu SD; Viale A; Tallman MS; Hyman DM; Reznik E; Finley LWS; Papaemmanuil E; Tosolini A; Frattini MG; MacBeth KJ; Liu G; Fan B; Choe S; Wu B; Janjigian YY; Mellinghoff IK; Diaz LA; Levine RL; Abou-Alfa GK; Stein EM; Intlekofer AM
Cancer Discov; 2018 Dec; 8(12):1540-1547. PubMed ID: 30355724
[TBL] [Abstract][Full Text] [Related]
16. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.
Ward PS; Patel J; Wise DR; Abdel-Wahab O; Bennett BD; Coller HA; Cross JR; Fantin VR; Hedvat CV; Perl AE; Rabinowitz JD; Carroll M; Su SM; Sharp KA; Levine RL; Thompson CB
Cancer Cell; 2010 Mar; 17(3):225-34. PubMed ID: 20171147
[TBL] [Abstract][Full Text] [Related]
17. What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer.
Losman JA; Kaelin WG
Genes Dev; 2013 Apr; 27(8):836-52. PubMed ID: 23630074
[TBL] [Abstract][Full Text] [Related]
18. Targeting IDH Mutations in AML: Wielding the Double-edged Sword of Differentiation.
Becker JS; Fathi AT
Curr Cancer Drug Targets; 2020; 20(7):490-500. PubMed ID: 32329690
[TBL] [Abstract][Full Text] [Related]
19. Targeting isocitrate dehydrogenase (IDH) in cancer.
Fujii T; Khawaja MR; DiNardo CD; Atkins JT; Janku F
Discov Med; 2016 May; 21(117):373-80. PubMed ID: 27355333
[TBL] [Abstract][Full Text] [Related]
20. Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations.
Intlekofer AM; Shih AH; Wang B; Nazir A; Rustenburg AS; Albanese SK; Patel M; Famulare C; Correa FM; Takemoto N; Durani V; Liu H; Taylor J; Farnoud N; Papaemmanuil E; Cross JR; Tallman MS; Arcila ME; Roshal M; Petsko GA; Wu B; Choe S; Konteatis ZD; Biller SA; Chodera JD; Thompson CB; Levine RL; Stein EM
Nature; 2018 Jul; 559(7712):125-129. PubMed ID: 29950729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
